Develops ophthalmic products for the treatment of eye diseases, focusing on innovative therapies to improve patient outcomes.
Kala Pharmaceuticals, Inc. is a biopharmaceutical company specializing in the discovery, development, and commercialization of therapies utilizing its proprietary mucus-penetrating particles technology, with a primary focus on treating eye diseases. The company's innovative approach is exemplified by its diverse pipeline of product candidates.
Among its leading candidates is KPI-012, currently in clinical development for addressing persistent corneal epithelial defects. Another notable product, EYSUVIS, targets the short-term treatment of dry eye disease symptoms. Additionally, INVELTYS, a topical ocular steroid administered twice daily, is designed to manage post-operative inflammation and pain following ocular surgery.
In the realm of preclinical development, Kala Pharmaceuticals is advancing KPI-287, a promising therapy that inhibits vascular endothelial and platelet-derived growth factors, intended for treating retinal diseases such as wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. The company also explores a selective glucocorticoid receptor modulators program, pioneering compounds that regulate gene expression via the transrepression pathway while circumventing the transactivation pathway.
Founded in 2009 and originally known as Hanes Newco, Inc., Kala Pharmaceuticals underwent a name change in December 2009 to reflect its focused mission in the pharmaceutical sector. Headquartered in Watertown, Massachusetts, the company continues to lead advancements in ocular therapies, aiming to improve outcomes for patients globally with innovative treatments for a range of eye-related conditions.